Bupropion Normalizes Cognitive Performance in Patients With Depression

C. Thomas Gualtieri, MD; Lynda G. Johnson, PhD

In This Article

Acknowledgements & Disclosures

Drs. Gualtieri and Johnson are two of the developers of the CNS Vital Signs screening battery. Dr. Gualtieri has conducted clinical trials on behalf of AstraZeneca, Bristol-Myers Squibb, Celltech, Cephalon, Eli Lilly, GlaxoSmithKline, Medeva, Organon, Shire, Wyeth-Ayerst, and UCB Pharma. He has been a speaker for and/or consultant to Eli Lilly, GlaxoSmithKline, Pfizer, Shire, and Wyeth. This research was supported by North Carolina Neuropsychiatry, PA, in Chapel Hill and Charlotte, and by CNS Vital Signs LLC. This study was supported by a grant to the investigators from GlaxoSmithKline.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: